Who are interruption of Glivec®'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Chemotherapy + Imatinib, Mercaptopurine, Imatinib, Inlyta, Axitinib (AG-013736), Icotinib plus WBRT, pazopanib or guideline conform chemotherapy.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/interruption-of-glivec.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

interruption of Glivec® — Competitive Intelligence Brief

interruption of Glivec® (interruption of Glivec®) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: tyrosine kinase inhibitor. Area: Oncology.

phase 3 tyrosine kinase inhibitor BCR-ABL, c-KIT, PDGFR Oncology Small molecule Live · refreshed every 30 min

Target snapshot

interruption of Glivec® (interruption of Glivec®) — Centre Leon Berard. Glivec is a tyrosine kinase inhibitor that targets BCR-ABL, c-KIT, and PDGFR.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
interruption of Glivec® TARGET	interruption of Glivec®	Centre Leon Berard	phase 3	tyrosine kinase inhibitor	BCR-ABL, c-KIT, PDGFR
Chemotherapy + Imatinib	Chemotherapy + Imatinib	Gruppo Italiano Malattie EMatologiche dell'Adulto	phase 3	Tyrosine kinase inhibitor + chemotherapy combination	BCR-ABL, c-KIT, PDGFR
Mercaptopurine, Imatinib	Mercaptopurine, Imatinib	St. Jude Children's Research Hospital	phase 3	Purine analog antimetabolite and tyrosine kinase inhibitor combination	Purine metabolism enzymes (mercaptopurine); BCR-ABL, c-KIT, PDGFR (imatinib)
Inlyta	Axitinib	Pfizer	marketed	Receptor tyrosine kinase inhibitor	Vascular endothelial growth factor receptors (VEGFR)-1, VEGFR-2, VEGFR-3	2012-01-01
Axitinib (AG-013736)	axitinib-ag-013736	Pfizer	marketed	tyrosine kinase inhibitor	vascular endothelial growth factor receptors (VEGFRs)
Icotinib plus WBRT	Icotinib plus WBRT	Betta Pharmaceuticals Co., Ltd.	marketed	EGFR tyrosine kinase inhibitor	EGFR (epidermal growth factor receptor)
pazopanib or guideline conform chemotherapy	pazopanib or guideline conform chemotherapy	GWT-TUD GmbH	marketed	Multi-targeted tyrosine kinase inhibitor	VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-α, PDGFR-β, c-Kit

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (tyrosine kinase inhibitor class)

Centre Leon Berard · 2 drugs in this class
Akeso · 1 drug in this class
Astex Pharmaceuticals, Inc. · 1 drug in this class
Chengdu Zenitar Biomedical Technology Co., Ltd · 1 drug in this class
Jiangsu HengRui Medicine Co., Ltd. · 1 drug in this class
Jiangsu ShengDiYa Medicine Co., Ltd. · 1 drug in this class
Nanjing Leads Biolabs Co.,Ltd · 1 drug in this class
Ocular Therapeutix, Inc. · 1 drug in this class
Peking University Cancer Hospital & Institute · 1 drug in this class
Pfizer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). interruption of Glivec® — Competitive Intelligence Brief. https://druglandscape.com/ci/interruption-of-glivec. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab